WST-057 for Neuropathy

"Yes, according to clinicaltrials.gov this trial has been open since February 24th 2022 and is actively in search of participants. A total of 60 people are being recruited from 3 separate sites."

"Confirmed. According to the information posted on clinicaltrials.gov, this research endeavour, first announced in February of 2022 and recently updated in November, is actively recruiting participants from 3 medical facilities for a total of 60 patients."

"This clinical trial seeks 60 participants aged between 18 and 80 who are suffering from polyneuropathy. Eligible persons must be male or female, with females of childbearing age requiring either no access to contraception (due to menopause) or a highly effective medically acceptable method such as hormonal contraceptives, intrauterine devices/systems, vasectomy (in the partner), or an approved combination of barrier methods like condoms. Additionally all subjects need to attend the required study visits on schedule."

"This clinical trial will be assessing the incidence of Treatment Emergent Adverse Events over a 16-week period as judged by vital signs such as blood pressure, heart rate, and respiratory rate. Secondary outcomes include Patient's Global Impression of Change (PGIC), Medical Outcomes Study HIV Health Survey (MOS-HIV) and Neuropathy Total Symptom Score-6 (NTSS-6). PGIC is evaluated with a 7 point scale measuring "much improved" to "much worse," whereas MOS-HIV encompasses 35 items related to health perceptions, pain management etc., scored on a 0 - 100 scale;"

"According to the eligibility requirements of this clinical trial, prospective participants must be between 18 and 80 years old."

"The therapeutic agent WST-057 was rated a 2 on our safety index, as it is currently in phase 2 trials and there is only preliminary evidence indicating its safety."